Literature DB >> 16159155

Chemistry and structural biology of androgen receptor.

Wenqing Gao1, Casey E Bohl, James T Dalton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16159155      PMCID： PMC2096617          DOI： 10.1021/cr020456u

Source DB:  PubMed          Journal:  Chem Rev        ISSN： 0009-2665            Impact factor:   60.622


× No keyword cloud information.
  144 in total

1.  Differential regulation of testosterone vs. 5alpha-dihydrotestosterone by selective androgen response elements.

Authors:  P W Hsiao; T H Thin; D L Lin; C Chang
Journal:  Mol Cell Biochem       Date:  2000-03       Impact factor: 3.396

Review 2.  Principles for modulation of the nuclear receptor superfamily.

Authors:  Hinrich Gronemeyer; Jan-Ake Gustafsson; Vincent Laudet
Journal:  Nat Rev Drug Discov       Date:  2004-11       Impact factor: 84.694

Review 3.  Structural development of biological response modifiers based on thalidomide.

Authors:  Yuichi Hashimoto
Journal:  Bioorg Med Chem       Date:  2002-03       Impact factor: 3.641

Review 4.  Molecular biology of steroid hormone synthesis.

Authors:  W L Miller
Journal:  Endocr Rev       Date:  1988-08       Impact factor: 19.871

5.  Approximate matching of regular expressions.

Authors:  E W Myers; W Miller
Journal:  Bull Math Biol       Date:  1989       Impact factor: 1.758

6.  A canonical structure for the ligand-binding domain of nuclear receptors.

Authors:  J M Wurtz; W Bourguet; J P Renaud; V Vivat; P Chambon; D Moras; H Gronemeyer
Journal:  Nat Struct Biol       Date:  1996-01

7.  RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism.

Authors:  T Battmann; A Bonfils; C Branche; J Humbert; F Goubet; G Teutsch; D Philibert
Journal:  J Steroid Biochem Mol Biol       Date:  1994-01       Impact factor: 4.292

8.  Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.

Authors:  Mark E Salvati; Aaron Balog; Donna D Wei; Dacia Pickering; Ricardo M Attar; Jieping Geng; Cheryl A Rizzo; John T Hunt; Marco M Gottardis; Roberto Weinmann; Rogelio Martinez
Journal:  Bioorg Med Chem Lett       Date:  2005-01-17       Impact factor: 2.823

9.  A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.

Authors:  P Schellhammer; R Sharifi; N Block; M Soloway; P Venner; A L Patterson; M Sarosdy; N Vogelzang; J Jones; G Kolvenbag
Journal:  Urology       Date:  1995-05       Impact factor: 2.649

Review 10.  Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans.

Authors:  Alain Bélanger; Georges Pelletier; Fernand Labrie; Olivier Barbier; Sarah Chouinard
Journal:  Trends Endocrinol Metab       Date:  2003-12       Impact factor: 12.015
View more
  119 in total

Review 1.  Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.

Authors:  Fraser F Fleming; Lihua Yao; P C Ravikumar; Lee Funk; Brian C Shook
Journal:  J Med Chem       Date:  2010-08-30       Impact factor: 7.446

2.  Activity landscape analysis of novel 5α-reductase inhibitors.

Authors:  J Jesús Naveja; Francisco Cortés-Benítez; Eugene Bratoeff; José L Medina-Franco
Journal:  Mol Divers       Date:  2016-02-01       Impact factor: 2.943

Review 3.  Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase?

Authors:  Wenqing Gao; James T Dalton
Journal:  Mol Interv       Date:  2007-02

4.  Methoxychalcone inhibitors of androgen receptor translocation and function.

Authors:  Yeong Sang Kim; Vineet Kumar; Sunmin Lee; Aki Iwai; Len Neckers; Sanjay V Malhotra; Jane B Trepel
Journal:  Bioorg Med Chem Lett       Date:  2012-01-21       Impact factor: 2.823

5.  Proteomic analyses to identify novel therapeutic targets for the treatment of advanced prostate cancer.

Authors:  Barbara Comuzzi; Marianne D Sadar
Journal:  Cellscience       Date:  2006-07-27

6.  Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.

Authors:  Aristomenis Anestis; Panagiotis Sarantis; Stamatios Theocharis; Ilianna Zoi; Dimitrios Tryfonopoulos; Athanasios Korogiannos; Anna Koumarianou; Evangelia Xingi; Dimitra Thomaidou; Michalis Kontos; Athanasios G Papavassiliou; Michalis V Karamouzis
Journal:  J Cancer Res Clin Oncol       Date:  2019-02-25       Impact factor: 4.553

7.  Synthesis and structure-activity relationship studies of novel dihydropyridones as androgen receptor modulators.

Authors:  Antonella Pepe; Michael Pamment; Yeong Sang Kim; Sunmin Lee; Min-Jung Lee; Kristin Beebe; Anton Filikov; Len Neckers; Jane B Trepel; Sanjay V Malhotra
Journal:  J Med Chem       Date:  2013-10-30       Impact factor: 7.446

Review 8.  The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.

Authors:  Elan Diamond; María del Carmen Garcias; Beerinder Karir; Scott T Tagawa
Journal:  Curr Treat Options Oncol       Date:  2015-02

9.  Structure of the ligand-binding domain (LBD) of human androgen receptor in complex with a selective modulator LGD2226.

Authors:  Feng Wang; Xiao-qin Liu; He Li; Kai-ni Liang; Jeffrey N Miner; Mei Hong; E Adam Kallel; Arjan van Oeveren; Lin Zhi; Tao Jiang
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-10-25

10.  MixMD Probeview: Robust Binding Site Prediction from Cosolvent Simulations.

Authors:  Sarah E Graham; Noah Leja; Heather A Carlson
Journal:  J Chem Inf Model       Date:  2018-06-26       Impact factor: 4.956
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.